6-{[tert-butyl(diphenyl)silyl]oxy}-2-methylhexan-3-ol | 907190-73-2

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 6-{[tert-butyl(diphenyl)silyl]oxy}-2-methylhexan-3-ol
• 英文别名: 6-[tert-butyl(diphenyl)silyl]oxy-2-methylhexan-3-ol
• CAS: 907190-73-2
• 化学式: C₂₃H₃₄O₂Si
• 分子量: 370.607
• InChiKey: YDGGCOHCYSJUQV-UHFFFAOYSA-N

物化性质

• 沸点：
  433.6±37.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.36
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-{[tert-butyl(diphenyl)silyl]oxy}-2-methylhexan-3-ol 在 palladium on activated charcoal 吡啶 、 4-二甲氨基吡啶 、 sodium azide 、 四丁基氟化铵 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-{[3-(3,5-dichlorophenyl)-1-(2-naphthyl)-1H-pyrazol-5-yl]oxy}-N-(4-hydroxy-1-isopropylbutyl)propanamide
  参考文献：
  名称：

  Diaryl substituted pyrazoles as potent CCR2 receptor antagonists

  摘要：

  We have identified and synthesized a series of diaryl substituted pyrazoles as potent antagonists of the chemokine receptor subtype 2. Structure-activity relationship studies directed toward improving the potency led to the discovery of 23 (IC50 = 6 nM). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.060
• 作为产物：
  描述：

  4-(tret-butyldiphenylsilyloxy)butan-1-ol 在 N-甲基吲哚酮 、 四丙基高钌酸铵 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 生成 6-{[tert-butyl(diphenyl)silyl]oxy}-2-methylhexan-3-ol
  参考文献：
  名称：

  Diaryl substituted pyrazoles as potent CCR2 receptor antagonists

  摘要：

  We have identified and synthesized a series of diaryl substituted pyrazoles as potent antagonists of the chemokine receptor subtype 2. Structure-activity relationship studies directed toward improving the potency led to the discovery of 23 (IC50 = 6 nM). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.060

文献信息

• Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
  申请人：Lim Jongwon

  公开号：US20070099950A1

  公开（公告）日：2007-05-03

  The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α 2 δ-1 subunit of Ca channels.

  本发明涉及使用三唑-吡啶嗪化合物治疗神经病性疼痛的方法。本发明还涉及使用三唑-吡啶嗪化合物治疗精神和情绪障碍，例如精神分裂症、焦虑、抑郁、双相情感障碍和惊恐症，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应，药物成瘾、药物滥用、戒断症状和其他疾病。本发明还涉及新型的三唑-吡啶嗪化合物，它们选择性地结合到钙通道的α2δ-1亚单位上。
• Substituted Pyrazoles as Modulators of Chemokine Receptors
  申请人：Pinkerton Anthony B.

  公开号：US20080167322A1

  公开（公告）日：2008-07-10

  Substituted pyrazole compounds such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

  替代吡唑化合物，这些化合物由式I表示：用于调节CCR-2趋化因子受体，以预防或治疗炎症和免疫调节性疾病和疾病，包括过敏性疾病，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及自身免疫病理如类风湿性关节炎和动脉硬化;以及包含这些化合物的制药组合物和使用这些化合物和组合物。
• WO2006/88813
  申请人：——

  公开号：——

  公开（公告）日：——
• Diaryl substituted pyrazoles as potent CCR2 receptor antagonists
  作者：Anthony B. Pinkerton、Dehua Huang、Rowena V. Cube、John H. Hutchinson、Mary Struthers、Julia M. Ayala、Pasquale P. Vicario、Sima R. Patel、Thomas Wisniewski、Julie A. DeMartino、Jean-Michel Vernier

  DOI：10.1016/j.bmcl.2006.10.060

  日期：2007.2

  We have identified and synthesized a series of diaryl substituted pyrazoles as potent antagonists of the chemokine receptor subtype 2. Structure-activity relationship studies directed toward improving the potency led to the discovery of 23 (IC50 = 6 nM). (c) 2006 Elsevier Ltd. All rights reserved.